- Trials with a EudraCT protocol (44,352)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)
44,352 result(s) found.
Displaying page 800 of 2,218.
EudraCT Number: 2014-004664-38 | Sponsor Protocol Number: LACAC_L_04304 | Start Date*: 2015-03-25 | |||||||||||
Sponsor Name:Sanofi | |||||||||||||
Full Title: Safety Dermatological Evaluation: genital mucosa irritation - Product tested: Dermacyd PH_DETINLYN Tangerine Mix. | |||||||||||||
Medical condition: Healthy volunteers (hygiene) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004666-14 | Sponsor Protocol Number: LACAC_L_04678 | Start Date*: 2015-03-25 | |||||||||||
Sponsor Name:Sanofi | |||||||||||||
Full Title: Safety Dermatological Evaluation: acceptability with pediatric follow up – Dermacyd Infantile LACAC_L_04678 | |||||||||||||
Medical condition: Healthy volunteers (hygiene) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003680-38 | Sponsor Protocol Number: HDVitC | Start Date*: 2015-06-12 |
Sponsor Name:VU university medical center | ||
Full Title: Pharmacokinetics of two different high dose regimes of intravenous vitamin C in critically ill patients | ||
Medical condition: Critically ill patients with trauma or sepsis exhibit a high degree of vitamin C deficiency at ICU admission and vitamin C plasma concentrations decrease even more during the first three days of ad... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-002147-28 | Sponsor Protocol Number: SALTO | Start Date*: 2013-09-06 | |||||||||||
Sponsor Name:Dutch Colorectal Cancer Group | |||||||||||||
Full Title: S-1 versus capecitabine in the first line treatment of metastatic colorectal cancer patients, the SALTO randomised phase III study of the Dutch Colorectal Cancer Group. A safety evaluation of oral ... | |||||||||||||
Medical condition: Metastatic Colorectal Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001323-23 | Sponsor Protocol Number: CH/2013/4247 | Start Date*: 2015-07-03 | ||||||||||||||||
Sponsor Name:University Hospitals Bristol NHS Foundation Trust | ||||||||||||||||||
Full Title: A phase II trial of Tocilizumab in anti-TNF refractory patients with JIA associated uveitis. | ||||||||||||||||||
Medical condition: Juvenile Idiopathic Arthritis with Associated Uveitis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-004163-21 | Sponsor Protocol Number: A0661157 | Start Date*: 2015-04-06 | |||||||||||
Sponsor Name:Pfizer Inc | |||||||||||||
Full Title: Phase 2/3, Open-Label, Comparative Trial Of Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In Children In Africa | |||||||||||||
Medical condition: Malaria | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004155-32 | Sponsor Protocol Number: 3090A1-301 | Start Date*: 2015-04-06 | |||||||||||
Sponsor Name:Wyeth Research | |||||||||||||
Full Title: An Open-Label, Single-Arm, Safety and Efficacy Study of Recombinant Human Factor IX (rFIX; BeneFIX ) in Children Less Than 6 Years of Age With Severe Hemophilia B | |||||||||||||
Medical condition: Hemophilia B | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004108-31 | Sponsor Protocol Number: RHB-104-03 | Start Date*: 2015-08-27 | |||||||||||
Sponsor Name:RedHill Biopharma Ltd. | |||||||||||||
Full Title: A Phase III Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects with Moderately Active Cr... | |||||||||||||
Medical condition: Moderately Active Crohn's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004162-17 | Sponsor Protocol Number: A0501061 | Start Date*: 2015-03-24 |
Sponsor Name:Pfizer Inc | ||
Full Title: A Multicenter, 10-Week, Randomized, Double-Blind Study Of Sertraline And Placebo In Children And Adolescents With Posttraumatic Stress Disorder (PTSD) | ||
Medical condition: Post-Traumatic Stress Disorder | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2011-003731-63 | Sponsor Protocol Number: 114351 | Start Date*: 2015-05-13 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase IV, open, multi-centre study to assess the immunogenicity, reactogenicity and safety of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy Taiwanese... | ||
Medical condition: Healthy volunteers (Two-dose primary vaccination at 2 and 4 months of age in healthy infants previously unin-fected with HRV infection) | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-001452-28 | Sponsor Protocol Number: RBHP_2014_CLAVELOU_2 | Start Date*: 2014-05-16 |
Sponsor Name:CHU de Clermont-Ferrand | ||
Full Title: . | ||
Medical condition: | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-004766-40 | Sponsor Protocol Number: 6096A1-3004 | Start Date*: 2015-04-10 |
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. | ||
Full Title: A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine In Healthy Infants Given With Rout... | ||
Medical condition: Pneumococcal disease | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2008-002066-57 | Sponsor Protocol Number: 3151A6-2000 | Start Date*: 2015-04-03 |
Sponsor Name:Wyeth Research | ||
Full Title: Multicenter, Open-Label, Safety, Tolerability, and Pharmacokinetic Study to Evaluate Single Ascending Doses and Subsequent Short-Term Administration of Fixed Doses of Desvenlafaxine Succinate Susta... | ||
Medical condition: Major Depressive Disorder | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2015-000585-61 | Sponsor Protocol Number: ALID02003 | Start Date*: 2015-05-18 | |||||||||||
Sponsor Name:Genzyme, a Sanofi Company | |||||||||||||
Full Title: A Multicenter, Multinational, Open-Label Study of Anti-Laronidase Antibody Formation and Urinary GAG Levels in Patients with Mucopolysaccaridosis I (MPS I) Being Treated with Aldurazyme® (laronidase) | |||||||||||||
Medical condition: Mucopolysaccharidosis I Hurler's Syndrome Hurler-Scheie Syndrome Scheie's Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001547-37 | Sponsor Protocol Number: 113552 | Start Date*: 2015-06-11 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A Phase I, double-blind, randomised, placebo controlled study to evaluate the reactogenicity and safety of a single oral dose of GlaxoSmithKline (GSK) Biologicals’ live attenuated liquid human rota... | ||
Medical condition: Rotavirus gastroenteritis | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2013-004137-32 | Sponsor Protocol Number: 111-202 | Start Date*: 2014-04-03 | |||||||||||
Sponsor Name:BioMarin Pharmaceutical Inc. | |||||||||||||
Full Title: A Phase 2, Open-label, Sequential Cohort Dose-escalation Study of BMN 111 in Children with Achondroplasia | |||||||||||||
Medical condition: achondroplasia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003195-12 | Sponsor Protocol Number: CHUBX2012/29 | Start Date*: 2013-10-01 |
Sponsor Name:CHU de Bordeaux | ||
Full Title: A multicenter, two arms, randomized, open label clinical Phase IV study investigating the proportion of CMV seropositive kidney transplant recipients who will develop a CMV infection within the fir... | ||
Medical condition: CMV infection in CMV-seropositive de novo kidney transplant recipients receiving an immunosuppressive regimen. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-002427-15 | Sponsor Protocol Number: 105910 | Start Date*: 2015-06-01 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A phase III, partially double-blind clinical trial to evaluate the immu-nogenicity and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ combined DTPa-HBV-IPV/Hib vaccine (new formulation) as co... | ||
Medical condition: Primary immunization of healthy infants in the first year of life against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis diseases and, if applicable, Haemophilus influenzae type b disease. | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-002187-32 | Sponsor Protocol Number: DMSG03/14 | Start Date*: 2014-09-05 |
Sponsor Name:Danish Myeloma Study Group | ||
Full Title: A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagno... | ||
Medical condition: multiple myeloma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-001640-38 | Sponsor Protocol Number: ATTRACT | Start Date*: 2014-08-08 | |||||||||||
Sponsor Name:CHU DE POITIERS | |||||||||||||
Full Title: Efficacy of Aflibercept (Eylea®) on Type 3 choroidal neovascularization. | |||||||||||||
Medical condition: Retinal diseases (type 3 choroidal neovascularization) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
